Despite the unequivocal success of hematopoietic stem and progenitor cell gene therapy, limitations still exist including genotoxicity and variegation/silencing of transgene expression. A class of DNA regulatory elements known as chromatin insulators (CIs) can mitigate both vector transcriptional silencing (barrier CIs) and vector-induced genotoxicity (enhancer-blocking CIs) and have been proposed as genetic modulators to minimize unwanted vector/genome interactions. Recently, a number of human, small-sized, and compact CIs bearing strong enhancer-blocking activity were identified. To ultimately uncover an ideal CI with a dual, enhancer-blocking and barrier activity, we interrogated these elements in vitro and in vivo. After initial screening of a series of these enhancer-blocking insulators for potential barrier activity, we identified three distinct categories with no, partial, or full protection against transgene silencing. Subsequently, the two CIs with full barrier activity (B4 and C1) were tested for their ability to protect against position effects in primary cells, after incorporation into lentiviral vectors (LVs) and transduction of human CD34+ cells. B4 and C1 did not adversely affect vector titers due to their small size, while they performed as strong barrier insulators in CD34+ cells, both in vitro and in vivo, shielding transgene's long-term expression, more robustly when placed in the forward orientation. Overall, the incorporation of these dual-functioning elements into therapeutic viral vectors will potentially provide a new generation of safer and more efficient LVs for all hematopoietic stem cell gene therapy applications.
Get full access to this article
View all access options for this article.
References
1.
Cavazzana-CalvoM, Hacein-BeyS, de Saint BasileG, et al.Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 2000; 288:669–672.
2.
WuX, LiY, CriseB, et al.Transcription start regions in the human genome are favored targets for MLV integration. Science, 2003; 300:1749–1751.
3.
SchröderARW, ShinnP, ChenH, et al.HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002; 110:521–529.
4.
MontiniE, CesanaD, SchmidtM, et al.The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest, 2009; 119:964–975.
5.
CesanaD, RanzaniM, VolpinM, et al.Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther, 2014; 22:774–785.
6.
EmeryDW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther, 2011; 22:761–774.
7.
EllisJ. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther, 2005; 16:1241–1246.
8.
HoweSJ, MansourMR, SchwarzwaelderK, et al.Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest, 2008; 118:3143–3150.
9.
ZhouX, LiuQ, WangD, et al.The cHS4 chromatin insulator reduces the rate of retroviral vector-mediated gene dysregulation associated with aberrant vector transcription. Cytogenet Genome Res, 2017; 151:72–81.
10.
EichlerF, DuncanC, MusolinoPL, et al.Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med, 2017; 377:1630–1638.
11.
SessaM, LorioliL, FumagalliF, et al.Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet, 2016; 388:476–487.
12.
ServickK. Gene therapy clinical trial halted as cancer risk surfaces. Science 2021; doi: 10.1126/science.abl8782.
13.
AkerM, TubbJ, GrothAC, et al.Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther, 2007; 18:333–343.
FelsenfeldG, Burgess-BeusseB, FarrellC, et al.Chromatin boundaries and chromatin domains. Cold Spring Harb Symp Quant Biol, 2004; 69:245–250.
16.
RivellaS, CallegariJA, MayC, et al.The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol, 2000; 74:4679–4687.
17.
EmeryDW, YannakiE, TubbJ, et al.Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood, 2002; 100:2012–2019.
18.
ArumugamPI, ScholesJ, PerelmanN, et al.Improved human β-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther, 2007; 15:1863–1871.
19.
LiCL, XiongD, StamatoyannopoulosG, et al.Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther, 2009; 17:716–724.
20.
DespratR, BouhassiraEE. Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator. PLoS One, 2009; 4:e5956.
21.
EmeryDW, YannakiE, TubbJ, et al.A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A, 2000; 97:9150–9155.
22.
UchidaN, WashingtonKN, LapCJ, et al.Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. Mol Ther, 2011; 19:133–139.
23.
UrbinatiF, ArumugamP, HigashimotoT, et al.Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3′LTR. Mol Ther, 2009; 17:1527–1536.
WallaceJA, FelsenfeldG. We gather together: insulators and genome organization. Curr Opin Genet Dev, 2007; 17:400–407.
26.
LiuM, MauranoMT, WangH, et al.Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol, 2015; 33:198–203.
27.
QiuY, HuangS. CTCF-mediated genome organization and leukemogenesis. Leukemia, 2020; 34:2295–2304.
28.
HeurteauA, PerroisC, DepierreD, et al.Insulator-based loops mediate the spreading of H3K27me3 over distant micro-domains repressing euchromatin genes. Genome Biol, 2020; 21:193.
29.
CuddapahS, JothiR, SchonesDE, et al.Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains. Genome Res, 2009; 19:24–32.
30.
MutskovVJ, FarrellCM, WadePA, et al.The barrier function of an insulator couples high histone acetylation levels with specific protection of promoter DNA from methylation. Genes Dev, 2002; 16:1540–1554.
31.
PikaartMJ, Recillas-TargaF, FelsenfeldG. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev, 1998; 12:2852–2862.
32.
NganCY, WongCH, TjongH, et al.Chromatin interaction analyses elucidate the roles of PRC2-bound silencers in mouse development. Nat Genet, 2020; 52:264–272.
33.
WethO, PaprotkaC, GüntherK, et al.CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin. Nucleic Acids Res, 2014; 42:11941–11951.
34.
HerbstF, BallCR, TuortoF, et al.Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. Mol Ther, 2012; 20:1014–1021.
35.
BokhovenM, StephenSL, KnightS, et al.Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol, 2009; 83:283–294.
36.
ScholzSJ, FronzaR, BartholomäCC, et al.Lentiviral vector promoter is decisive for aberrant transcript formation. Hum Gene Ther, 2017; 28:875–885.
37.
WaiAWK, GillemansN, Raguz-BolognesiS, et al.HS5 of the human β-globin locus control region: a developmental stage-specific border in erythroid cells. EMBO J, 2003; 22:4489–4500.
38.
ZuinJ, DixonJR, van der ReijdenMIJA, et al.Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells. Proc Natl Acad Sci U S A, 2014; 111:996–1001.
39.
TangY, JiaZ, XuH, et al.Mechanism of REST/NRSF regulation of clustered protocadherin α genes. Nucleic Acids Res, 2021; 49:4506–4521.
40.
ZhouQ, YuM, Tirado-MagallanesR, et al.ZNF143 mediates CTCF-bound promoter–enhancer loops required for murine hematopoietic stem and progenitor cell function. Nat Commun, 2021; 12:1–12.
41.
AiutiA, BiascoL, ScaramuzzaS, et al.Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 2013; 341:1233151.
42.
MarktelS, ScaramuzzaS, CicaleseMP, et al.Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β-thalassemia. Nat Med, 2019; 25:234–241.
43.
ThompsonAA, WaltersMC, KwiatkowskiJ, et al.Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med, 2018; 378:1479–1493.
44.
KalbererCP, PawliukR, ImrenS, et al.Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human β-globin in engrafted mice. Proc Natl Acad Sci U S A, 2000; 97:5411–5415.
45.
EyquemJ, Mansilla-SotoJ, GiavridisT, et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 2017; 543:113–117.
46.
LuX-B, GuoY-H, HuangW. Characterization of the cHS4 insulator in mouse embryonic stem cells. FEBS Open Bio, 2020; 10:644–656.
47.
Mansilla-SotoJ, RiviereI, BouladF, et al.Cell and gene therapy for the beta-thalassemias: advances and prospects. Hum Gene Ther, 2016; 27:295–304.
48.
ArumugamPI, HigashimotoT, UrbinatiF, et al.Genotoxic potential of lineage-specific lentivirus vectors carrying the β-globin locus control region. Mol Ther, 2009; 17:1929–1937.
49.
ElginSCR, ReuterG. Position-effect variegation, heterochromatin formation, and gene silencing in Drosophila. Cold Spring Harb Perspect Biol, 2013; 5:a017780.
50.
FestensteinR, TolainiM, CorbellaP, et al.Locus control region function and heterochromatin-induced position effect variegation. Science, 1996; 271:1123–1125.
51.
YannakiE, TubbJ, AkerM, et al.Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol Ther, 2002; 5:589–598.
52.
YaoS, OsborneCS, BharadwajRR, et al.Retrovirus silencer blocking by the cHS4 insulator is CTCF independent. Nucleic Acids Res, 2003; 31:5317–5323.
53.
BellAC, WestAG, FelsenfeldG. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell, 1999; 98:387–396.
54.
SplinterE, HeathH, KoorenJ, et al.CTCF mediates long-range chromatin looping and local histone modification in the β-globin locus. Genes Dev, 2006; 20:2349–2354.
55.
FarrellCM, WestAG, FelsenfeldG. Conserved CTCF insulator elements flank the mouse and human β-globin loci. Mol Cell Biol, 2002; 22:3820–3831.
56.
WestAG, HuangS, GasznerM, et al.Recruitment of histone modifications by USF proteins at a vertebrate barrier element. Mol Cell, 2004; 16:453–463.
57.
AkerM, BomsztykK, EmeryDW. Poly(ADP-ribose) polymerase-1 (PARP-1) contributes to the barrier function of a vertebrate chromatin insulator. J Biol Chem, 2010; 285:37589–37597.
58.
SzaboQ, BantigniesF, CavalliG. Principles of genome folding into topologically associating domains. Sci Adv, 2019; 5:eaaw1668.
59.
DixonJR, SelvarajS, YueF, et al.Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature, 2012; 485:376–380.
60.
DavidsonIF, BauerB, GoetzD, et al.DNA loop extrusion by human cohesin. Science, 2019; 366:1338–1345.
61.
GhirlandoR, FelsenfeldG. CTCF: making the right connections. Genes Dev, 2016; 30:881–891.
62.
GuoY, XuQ, CanzioD, et al.CRISPR inversion of CTCF sites alters genome topology and enhancer/promoter function. Cell, 2015; 162:900–910.
63.
GrothAC, LiuM, WangH, et al.Identification and characterization of enhancer-blocking insulators to reduce retroviral vector genotoxicity. PLoS One, 2013; 8:e76528.
de WitE, VosESM, HolwerdaSJB, et al.CTCF binding polarity determines chromatin looping. Mol Cell, 2015; 60:676–684.
66.
JiaZ, LiJ, GeX, et al.Tandem CTCF sites function as insulators to balance spatial chromatin contacts and topological enhancer-promoter selection. Genome Biol, 2020; 21:1–24.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
